微芯生物(688321.SH)收到国家知识产权局《无效宣告请求审查决定书》

智通财经05-08

智通财经APP讯，微芯生物(688321.SH)发布公告，公司于近日收到中华人民共和国国家知识产权局出具的《无效宣告请求审查决定书》(第610969号)。国家知识产权局专利局复审和无效审理部对无效宣告请求人南京正大天晴制药有限公司(简称“正大天晴”)提出的公司所持有的“一种TRKA(G667C)和FLT3靶点抑制剂及其与西达本胺的组合物”(专利号：ZL202211051615.8)的专利权之无效...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2633448434?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-08 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633448434","market":"us","top_or_hot":-1,"title":"微芯生物(688321.SH)收到国家知识产权局《无效宣告请求审查决定书》","media":"智通财经","content":"<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司于近日收到中华人民共和国国家知识产权局出具的《无效宣告请求审查决定书》(第610969号)。国家知识产权局专利局复审和无效审理部对无效宣告请求人南京正大天晴制药有限公司(简称“正大天晴”)提出的公司所持有的“一种TRKA(G667C)和FLT3靶点抑制剂及其与西达本胺的组合物”(专利号：ZL202211051615.8)的专利权之无效...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439630.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>微芯生物(688321.SH)收到国家知识产权局《无效宣告请求审查决定书》</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n微芯生物(688321.SH)收到国家知识产权局《无效宣告请求审查决定书》\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-08 18:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1439630.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，微芯生物(688321.SH)发布公告，公司于近日收到中华人民共和国国家知识产权局出具的《无效宣告请求审查决定书》(第610969号)。国家知识产权局专利局复审和无效审理部对无效宣告请求人南京正大天晴制药有限公司(简称“正大天晴”)提出的公司所持有的“一种TRKA(G667C)和FLT3靶点抑制剂及其与西达本胺的组合物”(专利号：ZL202211051615.8)的专利权之无效...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1439630.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1439630.html","article_id":"2633448434","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633448434","pubTimestamp":1778234859,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，微芯生物 发布公告，公司于近日收到中华人民共和国国家知识产权局出具的《无效宣告请求审查决定书》。案涉专利属于西达本胺专利保护体系中的工艺专利，根据该决定，七项核心权利要求维持有效，两项权利要求被宣告无效，案涉专利核心保护范围整体维持稳定，对阻止仿制药产品商业化的作用未发生实质性变化。综上，案涉西达本胺相关专利权被宣告部分无效的决定事项不会对公司的生产经营产生不利影响。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688321":"微芯生物","BK0239":"医药制造"},"translate_title":"Microchip Biotech (688321.SH) received the \"Decision on Review of Invalidation Request\" from the State Intellectual Property Office","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688321":1.5},"content_text":"智通财经APP讯，微芯生物(688321.SH)发布公告，公司于近日收到中华人民共和国国家知识产权局出具的《无效宣告请求审查决定书》(第610969号)。国家知识产权局专利局复审和无效审理部对无效宣告请求人南京正大天晴制药有限公司(简称“正大天晴”)提出的公司所持有的“一种TRKA(G667C)和FLT3靶点抑制剂及其与西达本胺的组合物”(专利号：ZL202211051615.8)的专利权之无效宣告请求进行了审查，审查结论为宣告专利权部分无效。案涉专利系公司产品西达本胺的工艺专利，公司围绕西达本胺已形成化合物、晶型、制剂、适应症等多项专利共同构建的专利保护体系，最长专利保护期已延长至2042年8月30日。案涉专利属于西达本胺专利保护体系中的工艺专利，根据该决定，七项核心权利要求维持有效，两项权利要求被宣告无效，案涉专利核心保护范围整体维持稳定，对阻止仿制药产品商业化的作用未发生实质性变化。此外，西达本胺仍然有适应症等其他专利进行保护。综上，案涉西达本胺相关专利权被宣告部分无效的决定事项不会对公司的生产经营产生不利影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633448434","isCrawlerRequest":true}